EVALUTION OF TREATMENT PATTERNS AMONG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Author(s)
Galaznik A1, Bell J1, Seal B2, Ogbonnaya A3, Hennenfent K4, Hamilton L4, Eaddy M4
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Xcenda, LLC, Scientific Consulting, Palm Harbor, FL, USA, 4Xcenda LLC, Palm Harbor, FL, USA
OBJECTIVES: : Treatment guidelines for DLBCL recommend a combination of chemotherapy agents with rituximab in first-line therapy (1LT). For patients with refractory/relapsed disease, high-dose chemotherapy with stem cell transplant, combination chemotherapy, or single-agent rituximab are considered. This study assessed real-world DLBCL treatment patterns as compared to guideline recommendations. METHODS: Patients newly diagnosed with DLBCL were identified between 01/01/08 and 08/31/15 within the Humedica electronic medical record (EMR). The first DLBCL diagnosis date served as the index date. Patients were required to have 12 months of continuous activity in the EMR before the index date, and were followed from index until end of continuous activity, death, or end of study period. DLBCL treatment patterns were assessed during follow-up. RESULTS: Of CONCLUSIONS: Consistent with guidelines, most first-line DLBCL patients received rituximab-based combinations. A small subset received 1LT monotherapy, which increased during subsequent lines of therapy, with rituximab as the most common 1LT and 2LTmonotherapy.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PCN284
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Treatment Patterns and Guidelines
Disease
Oncology